References

References

Department of Health. Abortion Statistics, England and Wales: 2012

European Medicines Agency (2005). Guideline on clinical investigation of steroid contraceptives in women. Doc. Ref. EMEA/CPMP/EWP/519/98 Rev 1

Faculty of Sexual & Reproductive Healthcare (2013). Subcutaneous depot medroxyprogesterone acetate (Sayana Press). New product review from the Clinical Effectiveness Unit

Health and Social Care information Centre (2013) NHS contraceptive services: England, 2012/13: community contraceptive clinics report

Jain J, Jakimiuk AJ, Bode FR et al. (2004). Contraceptive efficacy and safety of DMPA\u2011\SC. Contraception 70: 269–275

Kaunitz AM, Darney PD, Ross D et al. (2009). Subcutaneous DMPA vs. intramuscular DMPA: a 2\u2011\year randomized study of contraceptive efficacy and bone mineral density. Contraception 80: 7–17

Medicines and Healthcare products Regulatory Agency (2007) Sayana 104 mg/0.65 ml suspension for injection PL00057/0589 [online; accessed 3 December 2013]

Medicines and Healthcare products Regulatory Agency (2011) Sayana Press 104 mg/0.65 ml suspension for injection PL00057/1093http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con286921.pdf[online; accessed 3 December 2013]

National Institute for Health and Care Excellence (2013) Long-acting reversible contraception. NICE clinical guideline 30

Pfizer Ltd (2013) Sayana Press 104 mg/0.65 ml suspension for injection summary of product characteristics [online; accessed 3 December 2013]

Westhoff C, Jain JK, Milsom I et al. (2007). Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 ml. Contraception 75: 261–267